Answers are grounded in this paper and cite their sources.
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, plays a critical role in renal tubular injury in diabetic kidney disease (DKD). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a central regulator of cellular redox homeostasis and lipid peroxidation, thereby exerting a pivotal influence on ferroptosis. Urolithin A (UA), a gut microbiota-derived metabolite, exhibits potent antioxidant and anti-glycation properties and has demonstrated protective effects in diabetic models. This study aimed to investigate the renoprotective effects of UA in DKD and to determine whether these effects are mediated through inhibition of ferroptosis via activation of the Nrf2/HO-1 signaling pathway. A DKD model was established using db/db mice, which were randomly assigned to four groups: db/m , db/m + UA, db/db , and db/db + UA. After 10 weeks of UA administration by gavage, renal function, histopathological changes, and markers of oxidative stress and ferroptosis were evaluated. In vitro, HK-2 cells were exposed to high glucose to mimic the diabetic milieu, followed by UA treatment to assess cellular injury and associated molecular alterations. The involvement of the Nrf2 pathway was further validated by siRNA-mediated knockdown of Nrf2. UA significantly improved renal function in db/db mice, as indicated by decreased blood urea nitrogen and urinary albumin-to-creatinine ratio (UACR), along with marked attenuation of renal histopathological damage. UA effectively suppressed oxidative stress both in vivo and in vitro, as evidenced by reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), and increased glutathione (GSH) content. Furthermore, UA modulated ferroptosis-related proteins by downregulating ACSL4 and upregulating GPX4 and SLC7A11. These effects were accompanied by enhanced nuclear translocation of Nrf2 and increased expression of HO-1. Notably, Nrf2 knockdown largely abrogated the protective effects of UA. UA attenuates the progression of DKD by activating the Nrf2/HO-1 signaling pathway, thereby inhibiting oxidative stress and ferroptosis. These findings suggest that UA may serve as a promising therapeutic candidate for the treatment of DKD.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: